Health Decisions CEO Michael Rosenberg, MD, MPH, provides a comprehensive guide to the adaptive methods that are shaping the future of clinical trials
As drug developers face increasing legislative and market pressures to produce more impactful results faster and at lower cost, John Wiley & Sons Publishers announces a new book detailing the latest methods demonstrated to boost efficiency and innovation in clinical research. The Agile Approach to Adaptive Research: Optimizing Efficiency in Clinical Development will be released early 2010 with the aim of educating pharmaceutical, biotech and life science research professionals with new skills crucial to the financial health of the industry and the medical welfare of the global population.
Author Dr. Michael Rosenberg bases the book on more than twenty years of extensive research and clinical experience as founder and president of Health Decisions, a full-service CRO specializing in high-efficiency adaptive solutions. Under Dr. Rosenberg’s guidance, Health Decisions has achieved benchmark successes for its sponsors with its Agile Clinical Development platform—a flexible yet secure network of processes and technology that integrates adaptive design with adaptive operations. The Agile Approach to Adaptive Researchpresents a thorough explanation of the methodology and practical considerations behind this platform, which, according to Dr. Rosenberg consistently cuts 10 to 40 percent from traditional timelines.
For more information including a preview of The Agile Approach to Adaptive Research, please contact Courtney Cleaves, Marketing Manager at email@example.com.
“The Agile Approach to Adaptive Research presents a roadmap to a substantially faster, more efficient way of developing pharmaceuticals. This approach applies the same principles that have allowed other industries to make major leaps in productivity, but which are overdue in the pharmaceutical world. It shows the practical side of bringing drugs to market much faster while cutting costs and waste, in turn allowing more drugs to be developed and more people to be treated. The implications are quite profound.”
Dr. Michael Rosenberg
President and CEO